A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03944031

Enrollment

Registered

2019-05-09

Start date

2019-05-08

Completion date

2020-02-19

Last updated

2020-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.

Interventions

DIAGNOSTIC_TEST[18F]LSN3316612

Administered IV.

DRUGLY3372689

Administered orally.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Overtly healthy males or females who cannot get pregnant * Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study * Have veins and arteries suitable for protocol required blood sampling

Exclusion criteria

* Have a history of head injury or contraindications to undergoing magnetic resonance imaging (MRI) examination * Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study * Have previously participated or withdrawn from this study * Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure * Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study * Have long exposure to sunlight routinely or use tanning beds regularly * Participate in regular vigorous exercise

Design outcomes

Primary

Measure	Time frame	Description
Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)	Predose Scan (Days -14 to -1)	Percent OGA EO
Percent OGA EO	Postdose Scan 1 (Days 1 - 4)	Percent OGA EO

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026